Uncommon Manifestation of Oligometastatic Prostate Cancer-Reference-Cited by-同舟云学术

Uncommon Manifestation of Oligometastatic Prostate Cancer

Published:2023-03-06 Issue:5 Volume:48 Page:e225-e227
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Luna Cibele¹,Kryvenko Oleksandr N.,Martinez Jose,Singal Rakesh²,Kuker Russ¹

Affiliation:

1. Division of Nuclear Medicine, Department of Radiology, Jackson Memorial Hospital, University of Miami

2. Division of Medical Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL.

Abstract

Abstract A 76-year-old man with a history of prostate cancer diagnosed in 2008 developed biochemical recurrence in 2010 and started intermittent androgen deprivation therapy. In 2021, due to rising prostate-specific antigen, an 18F-piflufolastat PSMA PET/CT was performed. It showed a radiotracer-avid sclerotic lesion in the right iliac bone and an indeterminate radiotracer-avid nodule in the umbilical region, demonstrating progressive enlargement and increased uptake on subsequent imaging. Pathologic analysis of the umbilical nodule revealed metastatic prostate cancer—a finding eponymically referred to as a Sister Mary Joseph nodule.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference12 articles.

1. Advanced prostate cancer: treatment advances and future directions;Trends Cancer,2020

2. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer;JAMA,1998

3. A contemporary prostate cancer grading system: a validated alternative to the Gleason score;Eur Urol,2016

4. Prostate cancer, version 1.2016;J Natl Compr Canc Netw,2016

5. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial;JAMA Oncol,2019